IP Library Granted Patent US 10,485,818
Granted Patent B2
US 10,485,818 · App. 15/529,818 · Granted Nov 26, 2019

Dietary fibre composition

Inventors: Yee Mae Lim (Kuala Lumpur, MY); Pui Ee Wong (Kuala Lumpur, MY); Min Pau Tan (Kuala Lumpur, MY)
Assignee: INQPHARM GROUP SDN BHD
A61K31/736A23L2/52A23L29/244A23L29/256A23L29/27A23L33/10A23L33/21A23L33/30A61K31/723A61K31/731A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,485,818
App. No.
15/529,818
Granted
Nov 26, 2019
Kind
B2
Abstract

The invention provides a composition comprising glucomannan, carrageenan, xanthan gum and a monovalent or divalent cation salt. The composition is suitable for use in managing weight, combating obesity, combating metabolic syndrome, promoting satiety, reducing appetite, combating diabetes, lowering blood cholesterol, lowering blood pressure, reducing postpranial glycaemia, or increasing insulin sensitivity.

Claims (26)

1. A method of promoting satiety, reducing appetite, managing weight, combating obesity, managing blood glucose level, combating diabetes, lowering blood cholesterol, or combating metabolic syndrome, the method comprising administering to a subject a composition comprising glucomannan; carrageenan; xanthan gum; and a monovalent or divalent cation salt, wherein the glucomannan is present in an amount of 30-50% w/w by weight of the composition.

2. The method according to claim 1 , wherein the glucomannan is konjac glucomannan.

3. The method according to claim 1 , wherein the composition further comprises a therapeutic agent.

4. The method according to claim 3 , wherein the therapeutic agent is an absorption altering agent, an appetite altering agent, a metabolism altering agent, a cholesterol lowering agent or any combination thereof.

5. The method according to claim 1 , wherein the carrageenan is derived from a red algae.

6. The method according to claim 1 , wherein the red algae is selected from the group consisting of: Gigartinaceae; Solieriaceae; Hypneaceae; and Furcellariaceae.

7. The method according to claim 1 , wherein the carrageenan is kappa-carrageenan or iota-carrageenan.

8. The method according to claim 1 , wherein the monovalent or divalent cation salt is a water-soluble potassium salt.

9. The method according to claim 1 , wherein the potassium salt is selected from the group consisting of: potassium bicarbonate; potassium chloride; potassium acetate; potassium phosphate; and potassium citrate.

10. The method according to claim 1 , wherein the carrageenan is present in an amount of 15-25% w/w by weight of the composition.

11. The method according to claim 1 , wherein the xanthan gum is present in an amount of 10-25% w/w by weight of the composition.

12. The method according to claim 1 , wherein the potassium salt is present in an amount of 10-30% w/w by weight of the composition.

13. The method according to claim 1 , wherein the composition comprises 15-25% w/w carrageenan; 10-25% w/w xanthan gum; and 10-30% w/w monovalent or divalent cation salt.

14. The method according to claim 13 , wherein the composition comprises 40% w/w glucomannan; 24% w/w carrageenan; 16% w/w xanthan gum; and 20% w/w monovalent or divalent cation salt.

15. The method according to claim 1 , wherein the composition comprises 220-280 mg glucomannan; 140-160 mg carrageenan; 90-110 mg xanthan gum; and 90-160 mg monovalent or divalent cation salt.

16. The method according to claim 1 , wherein the composition comprises 250 mg glucomannan; 150 mg carrageenan; 100 mg xanthan gum; and 125 mg monovalent or divalent cation salt.

17. The method according to claim 1 , wherein the composition has a swelling index of at least 120 ml/g under a pH condition resembling the pH of a stomach.

18. The method according to claim 1 , wherein the composition has a swelling index of at least 250 mg/g under a pH condition resembling the pH of an intestine.

19. The method according to claim 1 , wherein the swelling volume of the composition is increased by at least 80 fold.

20. The method according to claim 1 , wherein the composition swells under a pH condition resembling the pH of a stomach or the pH of an intestine.

21. The method according to claim 1 , wherein the composition increases viscosity under pH condition resembling the pH of a stomach or the pH of an intestine.

22. The method according to claim 1 , wherein the composition gels under pH condition resembling the pH of a stomach or the pH of an intestine.

23. The method according to claim 1 , wherein the composition is in the form of a capsule, tablet, powder, syrup, solution, suspension, sachet or shake.

24. The method according to claim 1 , wherein the composition is a food product or beverage product.

25. The method according to claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier and/or excipient and/or diluent.

26. The method according to claim 24 , wherein the food beverage of product is a dietary supplement, a meal replacement, or a food additive.

Assignments (2)
NUNC PRO TUNC ASSIGNMENT Recorded Dec 3, 2021
From: INQPHARM GROUP SDN BHD
To: BIONEXUS LLC
Reel/Frame 058277/0958 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2018
From: LIM, YEE MAE; WONG, PUI EE; TAN, MIN PAU
To: INQPHARM GROUP SDN BHD
Reel/Frame 047781/0433 →
Priority Claims (1)
MY PI2014703525 · Nov 26, 2014 · national
Continuity (1)
Related Publication 20170319616A1 · Nov 9, 2017